TSS
ADVM

Two Sigma Securities’s Adverum Biotechnologies ADVM Stock Holding History

Two Sigma Securities’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,124
Closed -$87K – 699
2016
Q3 		$87K Buy
+2,124
New +$80.6K 0.03% 529

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Two Sigma Securities's ADVM Position: Q4 2016 in Review

Two Sigma Securities sold out of Adverum Biotechnologies (ADVM) in Q4 2016, closing a stake of 2,124 shares — an estimated $87K sold.

Two Sigma Securities first reported a position in ADVM in Q3 2016 and held it in 1 quarter. The position peaked at $87K in Q3 2016. 83 funds tracked by Wall St. Rank hold ADVM as of Q4 2016.

  • Two Sigma Securities reported no remaining Adverum Biotechnologies position as of Q4 2016 after selling out during the quarter.
  • Two Sigma Securities sold 2,124 Adverum Biotechnologies shares in Q4 2016, an estimated $87K.
  • Two Sigma Securities first reported a position in Adverum Biotechnologies in Q3 2016 and held it in 1 quarter.
  • Two Sigma Securities's Adverum Biotechnologies position peaked at $87K in Q3 2016.
  • 83 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2016.

Based on Two Sigma Securities's 13F filing for Q4 2016, filed 14 Feb 2017.